Background: The need to recognize Alzheimer's disease (AD) as early as possible led us to evaluate the predictive value of amyloid b(1-42) (Ab42), total tau (tau), and phosphorylated tau (ptau) in cerebrospinal fluid (CSF) for clinical progression in patients with subjective complaints. Methods: We recruited nondemented patients with subjective complaints (i.e., criteria for mild cognitive impairment [MCI] not fulfilled) from our memory clinic. We assessed the predictive value of CSF Ab42, tau, and ptau for clinical progression using Cox proportional hazards models adjusted for age, gender, and baseline findings on the Mini-Mental State Examination (MMSE). Clinical progression was defined as progression to MCI or AD. Results: We included 127 patients with subjective complaints (age 60 6 10 years, 61 [48%] females, MMSE 29 6 1). At baseline, Ab42 and tau were abnormal in 20 patients (both 16%), and ptau in 32 patients (25%). Thirteen patients (10%) progressed to MCI (n 5 11) or AD (n 5 2). Ab42 was the strongest predictor of progression to MCI or AD with an adjusted hazard ratio (HR) of 16.0 (3.8-66.4). The adjusted HR associated with tau was 2.8 (0.9-9.2) and with ptau 2.6 (0.8-8.2).
Introduction
Neuropathologic changes associated with Alzheimer's disease (AD) are thought to precede clinical dementia by many years [1] [2] [3] . Cerebrospinal fluid (CSF) markers of pathologic changes could be useful to identify persons in an early stage of AD when they have little or no cognitive impairment. Recognizing AD in an early stage will become very important with the introduction of disease-modifying therapies.
Patients with subjective complaints form a heterogeneous group. A considerable proportion of these patients are "worried well" and have no neurodegenerative disorder. A number of patients, however, may have early AD [4, 5] . Recently, the term "preclinical AD" was introduced by two different groups of investigators to refer to individuals who have biomarkers consistent with AD pathology, but-like patients with subjective complaints-do not fulfill criteria for mild cognitive impairment (MCI) or dementia [2, 6] . It was postulated these individuals would be most likely to show clinical progression.
There is ample evidence that CSF amyloid b(1-42) (Ab42), total tau (tau), and phosphorylated tau (ptau) predict progression to AD dementia in patients with MCI [7] [8] [9] [10] , and there have been a few population-based studies in which CSF biomarkers were related to cognitive decline in healthy subjects [11] [12] [13] . In contrast, only one study has considered the predictive value of CSF biomarkers in patients with subjective complaints [8] . That study showed the AD biomarker profile in patients with subjective complaints to be quite common [8] . There were some indications that patients with subjective complaints and an AD biomarker profile were more likely to show clinical progression, but this could not be shown conclusively, because hardly any progression was measured during follow-up [8] .
The need to recognize AD as early as possible prompted us to assess the predictive value of CSF Ab42, tau and ptau concentrations for clinical progression in a large group of patients with subjective complaints and a long period of follow-up.
Methods

Patients
We included patients who were considered to have subjective complaints from the Alzheimer Center of the VU University Medical Center, Amsterdam, between 2001 and 2007. At baseline, all patients underwent a standardized dementia screening, including physical and neurologic examination as well as laboratory tests, electroencephalography, (EEG) and brain magnetic resonance imaging (MRI). Cognitive assessment included the Mini-Mental State Examination (MMSE) and extensive neuropsychologic testing. Diagnoses were made in a multidisciplinary meeting, without knowledge of CSF results. Patients were labeled as having subjective complaints when they presented with cognitive complaints, but cognitive and laboratory investigations were normal and criteria for MCI, dementia, or any other neurologic or psychiatric disorders known to cause cognitive complaints were not met (i.e., cognitively normal elderly). Petersen's criteria were used for MCI as were criteria of the National Institute for Neurological and Communicative Diseases-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) for probable AD [14, 15] .
One hundred seventy-four of 446 patients with subjective complaints were eligible for our study, because they underwent lumbar puncture at baseline (Figure 1 ). Reasons for not undergoing lumbar puncture included contraindications (such as a coagulation disorder or use of coumarin) or refusal. To be included in the study, patients were required to have a minimal duration of follow-up of 2 years or to show clinical progression; 33 patients did not fulfill this inclusion criterion.
Five patients were not included, because they progressed to a form of dementia other than AD. Finally, 8 patients were excluded, because they received a different diagnosis within 6 months of baseline, suggesting a change of opinion on baseline diagnosis, rather than progression of disease. Thus, 128 patients were included in the analyses. Baseline characteristics did not differ between patients included in the analyses and those not included (data not shown).
Follow-up took place by routine visits to our memory clinic in which patient history, cognitive tests, and a general physical and neurologic examination were repeated. CSF results were not taken into account when follow-up diagnosis was established. Patients who did not undergo routine follow-up for at least 2 years after baseline were contacted by telephone and their cognitive status was evaluated by a standardized interview that included questions concerning all cognitive domains, physical complaints, and medical history, complemented by the Telephone Interview for Cognitive Status (TICS) [16, 17] . When the telephone interview gave rise to a suspicion of potential clinical progression, patients were invited for a more thorough investigation at the outpatient clinic. The primary outcome measure was clinical progression, defined as progression to MCI or AD.
The medical ethics committee of the VU University Medical Center approved the study. All patients provided written informed consent.
CSF analysis
CSF samples were obtained by lumbar puncture between the L3/L4 or L4/L5 intervertebral space by a 25-gauge needle and collected in polypropylene tubes. CSF was centrifuged at 1800 ! g for 10 minutes at 4 C. Part of the CSF was used for routine analysis, including leukocyte count, erythrocyte count, glucose concentration, and total protein. The remaining CSF was immediately frozen at 220 C until further analysis (within 2 months). CSF analysis took place at the neurology laboratory of the VU University Medical Center, Amsterdam. Ab42, tau, and ptau were measured using sandwich enzyme-linked immunoassays (ELISAs; Innotest beta-amyloid1-42, Innotest hTAU-Ag, and Innotest PhosphoTAU-181p; Innogenetics, Belgium), as described elsewhere [18] . The performance of these assays was monitored with internal quality control pools of surplus CSF (high and low biomarker values). Interassay coefficients of variation (CVs) were 11.3% (4.9%) for Ab42, 9.3% (1.5%) for tau, and 9.4% (2.5%) for ptau [18] .
There is no international consensus defining what constitutes an AD biomarker profile. Therefore, we evaluated each biomarker individually and in several combinations. For individual markers we used our own previously published reference values. The following values were considered indicative of AD pathology: ,550 ng/L for Ab42; .375 ng/L for tau; and .52 ng/L for ptau [18] . We also used the following combinations to construct an AD biomarker profile: (1) 
Statistical analysis
Data were analyzed using SPSS (version 18.0) for Macintosh. Baseline characteristics were compared using t-test, chi-square test, or Mann-Whitney U-test, as appropriate. Cox proportional hazards models were used to assess the predictive value of CSF biomarkers for clinical progression. Each biomarker and all previously mentioned combinations were evaluated as independent variables in separate analyses: the first model without adjustment; the second model adjusted for gender and age; the third model adjusted for gender, age, and baseline MMSE; and the fourth model adjusted for gender, age, baseline MMSE, and dichotomized apolipoprotein E (APOE) ε4 status. The third model included 124 patients, because baseline MMSE data were missing for 3 patients and the fourth included 118 patients, because APOE status was missing for 6 additional patients. Results are presented as hazard ratio (HR) with 95% confidence interval (CI). Kaplan-Meier curves were plotted for clinical progression with separate lines for normal and abnormal biomarker values. Differences between the curves of both groups were assessed using log-rank tests.
Results
One hundred twenty-eight patients were included in this study (age 60 6 10 years, 61 [48%] females, MMSE 29 6 1). Mean follow-up duration was 4 6 2 years. At baseline, Ab42 was abnormal in 20 patients (16%), tau was abnormal in 20-partly overlapping-patients (16%), and ptau was abnormal in 32 patients (25%). An AD biomarker profile, defined as decreased Ab42 combined with increased tau and/or ptau, occurred in 10 patients (8%).
Thirteen patients (10%) progressed to MCI (n 5 11) or AD (n 5 2). Progressors were older at baseline (Table 1) . There was a trend toward a gender difference between the groups with a predominance of men among the progressors.
Baseline MMSE was 28.7 6 1.3 in patients with stable subjective complaints and 28.0 6 1.7 in progressors. Concentrations of CSF Ab42 were lower (P 5 .001) and tau and ptau concentrations were higher in the progressors (P , .05). All biomarkers were between two and five times more frequently outside the reference range in the progressors (P , .001 for Ab42 and tau, P , .05 for ptau).
Of the individual biomarkers, Ab42 was the best predictor of clinical progression. The unadjusted HR of Ab42 was 11.6 (3.5-38.7) (Table 2 and Figure 2) . Adjustment for age, gender, baseline MMSE, and APOE status increased the HR of Ab42 to 16.0 (3.8-66.4). Tau and ptau clearly had less strong predictive values. Tau had an unadjusted HR of 4.0 (1.3-11.9), which decreased to 2.8 (0.9-9.2). The unadjusted HR of 3.2 (1.1-9.5) of ptau decreased to 2.6 (0.8-8.2).
In addition to evaluating individual biomarkers, we also studied several combinations that could represent an AD biomarker profile. Although all of these combinations predicted clinical progression, Ab42 alone remained the strongest predictor (see Table 2 ). The combination of low Ab42 with high tau and/or ptau resulted in an unadjusted HR of 9.0 (2.8-28.6). The first regression formula based on our own data resulted in an unadjusted HR of 5.7 (1.9-17.1) and the second regression formula based on previously published research resulted in an unadjusted HR of 4.7 (1.6-14.1). Adjustment for age, gender, baseline MMSE, and APOE status did not change any of the results.
Discussion
We found low CSF Ab42 concentration to be a very strong predictor of clinical progression in patients with subjective complaints, even after adjustment for well-known risk factors for AD. An AD biomarker profile can also predict clinical progression in patients with subjective complaints, but less well than Ab42 alone. We were able to show this in a relatively large group of patients who underwent standardized clinical follow-up with a mean duration of nearly 4 years. Our findings are in line with the amyloid cascade hypothesis. This hypothesis states that neuropathology of AD starts with aggregation of amyloid, followed by hyperphosphorylation and accumulation of tau and, eventually, neuronal loss [20, 21] . This hypothesis was recently incorporated in a dynamic biomarker view, which proposed that biomarkers have a temporal ordering that reflects the process of advancing AD neuropathology [22] . According to this dynamic biomarker view, CSF Ab42 becomes abnormal in a very early stage when a patient is still cognitively normal. CSF tau increases at a later stage, when the disease has progressed further [22] . Our findings provide supporting evidence for this dynamic biomarker view, especially when combined with the knowledge derived from previous MCI studies. In MCI, CSF tau or ptau concentrations have consistently been found to be better predictors of progression to AD dementia than Ab42 [23] [24] [25] [26] . Furthermore, combinations of biomarkers have been shown to perform even better [7, 23, 27, 28] . These differences between findings in patients with subjective complaints and MCI suggest that an AD biomarker profile does not develop at once. Ab42 has probably started to aggregate into oligomers and fibrils in the subjective complaints stage of AD, whereas tangle burden and neurodegeneration are not always sufficient to cause elevated CSF (p)tau. When patients reach the clinical MCI stage, more extensive neuronal loss has occurred, resulting in abnormal CSF tau and ptau concentrations and, consequently, a full-fledged AD biomarker profile. Temporal organization of these events explains why the best diagnostic biomarker for AD in CSF (an AD profile) could be different from the best prognostic biomarker in the earliest stages of the disease (Ab42).
In our study, a number of patients did not show clinical progression in spite of elevated tau or ptau values. With the previously mentioned dynamic biomarker view in mind, this may imply that elevated (p)tau has less clinical meaning when the earlier event of low Ab42 is absent.
Contrary to our expectations the predictive values of the three CSF AD profiles we used were very similar. Although interassay variation was previously shown to be large when individual concentrations of Ab42, tau, and ptau were assessed [29] , our results indicate that an AD profile, such as the one defined by Hulstaert et al, has sufficient external validity to predict clinical progression in patients with subjective complaints in a different cohort and laboratory than the one in which it was developed.
The prevalence of an AD biomarker profile in a previously published population-based sample without cognitive complaints was 12% [13] . We found a prevalence of 8% when using a similar definition of decreased Ab42 and increased tau or ptau. The prevalence of low Ab42 alone in our study was 16%, which seems comparable to the 20%-30% of healthy patients with increased Pittsburgh compound B (PiB) binding in PiB/positron emission tomography (PET) studies [30] [31] [32] [33] . The small difference can perhaps be explained by the fact the earlier studies evaluated participants older than those in our study [30] [31] [32] [33] . The only other study that included patients with subjective complaints as a separate group indicated a much higher prevalence of an AD biomarker profile. The prevalence was 52% when using the formula of Hulstaert et al [19] , which we also used as one of our combination markers [8] . This could have been due to analytical and preanalytical differences between the two laboratories, resulting in different absolute biomarker values and thereby in a different prevalence of the AD profile. However, in one previous study, 33 CSF samples were analyzed at both sites and the results were very similar (e.g., Ab42 values were 593 6 294 ng/L in Amsterdam and 558 6 246 ng/L in Gothenburg [P 5 .60]). Alternatively, the difference in the prevalence of AD biomarker profile in the two cohorts may be due to differences in age and genetic background of the study samples, as the subjects in the former study were older and had a higher prevalence of the APOE ε4 genotype. Subtle differences between inclusion criteria and definitions of categories used may also partly explain the differences between the two studies. A few other studies have assessed the predictive value of CSF biomarkers in patients without cognitive impairment [11, 13, 34, 35] , or groups of "healthy" subjects that may not have excluded MCI patients [12] . Consistent with our results, CSF Ab42 was found to be the best predictor of cognitive decline and dementia in several population-based samples [12, 34, 35] . Also, an AD profile predicted cognitive decline [11, 13, 35] . Recent PiB/PET studies indicated similar results, showing increased PiB binding to be predictive of clinical progression in healthy older subjects [30, 36, 37] . One of these imaging studies also included hippocampal atrophy and fludeoxyglucose/PET as markers for neurodegeneration [37] . Similar to our results both a positive PiB/PET scan and a combination of amyloid and neurodegenerative markers were associated with clinical progression [37] . In contrast to our findings, a study of 90 community-dwelling elderly with a clinical dementia rating scale (CDR) of 0, where CSF Ab42 alone was used, did not predict clinical progression, whereas an combination of CSF biomarkers did [11] . A more recent CSF study from the same [18] . Log rank tests were performed to assess the difference between both lines in each plot. All differences were significant (P ,.001 for Ab42 and the AD profile, P , .01 for tau, and P , .05 for ptau).
investigators assessed 213 subjects with a CDR score of 0, who were, on average, 10 years younger than those in the earlier study [35] . On this occasion, the results were more similar to ours: Ab42 performed best in the unadjusted models and just as well as the AD profiles in the adjusted models [35] . A likely explanation for the different results is that, because the participants were older, the earlier CSF study had patients with more advanced AD pathology. This is supported by a much higher progression rate in those studies, both in comparison to our current data and the more recent CSF study [11, 35] . Only one previous study assessed the predictive value of CSF biomarkers in a group of patients with subjective complaints [8] . In that study an AD biomarker profile was highly prevalent, but did not predict cognitive decline. The most likely explanation seems to be that a mean follow-up duration of 2.4 years was too short to detect any relevant progression. In general, it seems that our patients with subjective complaints were similar to "healthy" subjects of the same age taken from the general population, both in terms of amount of AD pathology present and predictive value of CSF biomarkers.
A major strength of the current study is that we utilized a relatively large patient cohort, with all participants undergoing an extensive and standardized clinical work-up. Also, patients were followed for a substantial amount of time. Among the possible limitations of our study is the outcome measure used. We used clinical diagnoses as outcome measures without pathologic confirmation. It is, however, unlikely that progressors had a different underlying pathology than AD, because the sensitivity of NINCDS-ADRDA criteria for AD is good and most of the MCI patients had amnestic MCI, which makes an underlying AD pathology likely [38] [39] [40] [41] .
The term "preclinical AD" seems to accurately describe patients with subjective complaints and CSF biomarkers consistent with AD, especially those with low Ab42 [2] . Our data suggest that the neuropathologic disease stage of patients with subjective complaints is best compared to that of individuals with the same CSF profile, without any complaints or impairment. Our patients, however, are in a unique position, because they do seek medical care, which makes them available for disease-modifying therapies at a time when the AD brain may still be salvageable [42] . In the future this could be of utmost importance with regard to the way patients are selected for clinical trials. Still, in our opinion, it is too early for diagnostic use of the term preclinical AD. Future studies with larger samples and longer follow-up will be needed to prove whether all individuals with low CSF Ab42 will eventually develop AD dementia or if clinical progression can still be prevented by (unknown) protective factors.
